Comparative Pharmacology
Head-to-head clinical analysis: ALYQ versus WIDAPLIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYQ versus WIDAPLIK.
ALYQ vs WIDAPLIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
WIDAPLIK is a small-molecule inhibitor of cyclin-dependent kinase 12 (CDK12). By selectively inhibiting CDK12, it interferes with the phosphorylation of RNA polymerase II, leading to reduced expression of DNA damage response genes and promoting apoptosis in cancer cells.
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
50 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 12 hours (range 10–14 h) in healthy adults; prolonged to 24–36 h in moderate renal impairment (CrCl 30–50 mL/min).
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Primarily renal excretion as unchanged drug (approximately 70%) with 20% as inactive metabolites; 10% via feces.
Category C
Category C
Unknown
Unknown